Weight evolution in girls treated for idiopathic central precocious puberty with GnRH analogues

J Pediatr Endocrinol Metab. 2006 Nov;19(11):1327-34. doi: 10.1515/jpem.2006.19.11.1327.

Abstract

Data concerning the effects of GnRHa on weight gain are scarce.

Objective: To assess the variation of the body mass index (BMI) in girls during GnRHa treatment for idiopathic central precocious puberty (CPP).

Patients and methods: Semestral anthropometric data from 176 girls treated with goserelin or leuprorelin were analyzed.

Results: BMI z-score increased from 1.5 +/- 0.1 SD before treatment (n = 176) to 1.7 +/- 0.2 SD after 24 months (n = 61, p = 0.008). In girls with normal weight before treatment, this variation was greater (n = 112, 0.2 +/- 0.1 SD, p = 0.01) than in those who were overweight (n = 63, -0.9 +/- 0.2 SD, p = 0.7). In the goserelin group the weight change adjusted for bone age was greater (n = 28, 0.4 +/- 0.1 SD) than in the leuprorelin group (n = 5, 0.04 +/- 0.1 SD, p = 0.05).

Conclusions: A slight increase in BMI was noted, mainly in girls with normal weight before treatment. The influence of different GnRHa on weight must be further investigated.

Publication types

  • Evaluation Study

MeSH terms

  • Body Height / drug effects
  • Body Height / physiology
  • Body Mass Index
  • Body Weight / drug effects
  • Body Weight / physiology*
  • Child
  • Child, Preschool
  • Female
  • Gonadotropin-Releasing Hormone / analogs & derivatives*
  • Goserelin / pharmacology
  • Goserelin / therapeutic use*
  • Humans
  • Leuprolide / pharmacology
  • Leuprolide / therapeutic use*
  • Longitudinal Studies
  • Puberty, Precocious / drug therapy*
  • Puberty, Precocious / physiopathology
  • Retrospective Studies

Substances

  • Goserelin
  • Gonadotropin-Releasing Hormone
  • Leuprolide